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Abstract
Dry age-related macular degeneration (AMD) is characterised by loss of central vision and currently has no approved
medical treatment. Dysregulation of the complement system is thought to play an important role in disease pathology and
supplementation of Complement Factor I (CFI), a key regulator of the complement system, has the potential to provide a
treatment option for AMD. In this study, we demonstrate the generation of AAV constructs carrying the human CFI
sequence and expression of CFI in cell lines and in the retina of C57BL/6 J mice. Four codon optimised constructs were
compared to the most common human CFI sequence. All constructs expressed CFI protein; however, most codon optimised
sequences resulted in significantly reduced CFI secretion compared to the non-optimised CFI sequence. In vivo expression
analysis showed that CFI was predominantly expressed in the RPE and photoreceptors. Secreted protein in vitreous humour
was demonstrated to be functionally active. The findings presented here have led to the formulation of an AAV-vectored
gene therapy product currently being tested in a first-in-human clinical trial in subjects with geographic atrophy secondary to
dry AMD (NCT03846193).
Introduction
Age-related macular degeneration (AMD) is the most
common cause of blindness amongst the elderly in the
industrialised world, affecting approximately 36 to 40
million people globally [1]. While the early stages of the
disease are characterised by slight disturbances in vision,
such as blurred or distorted vision, late stage forms can be
associated with severe sight loss that has a dramatic impact
on the lives of affected individuals. Late stage AMD is
divided into wet AMD and geographic atrophy (GA), the
former currently being treated with anti-VEGF therapeutics,
while for the latter there is currently no approved medical
treatment. The exact molecular pathways leading to disease
are not yet identified; however, it is established that AMD is
a complex disease and that genetic predisposition together
with environmental and demographic factors play a sig-
nificant role [1]. The complement system, a major effector
arm of innate and adaptive immunity, is thought be
involved in disease pathology. Complement proteins are
accumulated in drusen, one of the main hallmarks of early
AMD, and Bruch’s membrane; plasma, aqueous or vitreous
humour levels of complement activation fragments C3a,
C3dg, Bb and C5a are increased in AMD patients [2–4].
Genome wide association studies (GWAS) further revealed
an association of disease with key regulatory proteins of the
complement system [5, 6]. Moreover, oxidative stress was
linked to AMD through formation of neoepitopes that bind
to autoantibodies capable of activating complement [7, 8].
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The accumulation of complement proteins may act as a
depot of continual complement stimulation by triggering
local production of inflammatory mediators and attracting
leukocytes that further augment the local inflammatory
state, driving AMD pathology. Mutations in Complement
C3, Complement Factor I (CFI), Complement Factor H
(CFH) and Complement Factor B (CFB) genes strongly
correlate with the likelihood of developing AMD, with CFI
highlighted as particularly significant [5]. These findings
have since been confirmed in further independent studies
and low serum CFI levels associated with the presence of
rare CFI variants were found to be associated with a much
higher risk of developing advanced AMD (P= 5.6E-05)
[9, 10]. Together, these findings implicate loss of comple-
ment regulatory control in AMD pathogenesis.
The complement system is a critical component of the
immune system and can be activated via the classical, lectin,
or alternative pathway. The first two pathways are activated
by binding of their recognition molecules to IgG or IgM
immune complexes, C-reactive protein, pentraxin 3, RNA,
DNA, extracellular matrix proteins, altered self-structures
such as beta-amyloid, apoptotic or necrotic cells, micro-
organism derived ligands, like LPS or carbohydrate struc-
tures on microorganisms or altered self-cells [11]. The
alternative pathway (AP) can be activated on protected
surfaces [12] but mainly acts as a powerful amplification
mechanism of the other two pathways. It depends on the so-
called ‘tick-over’ mechanism (more recently described in
[13]) and is initiated by binding of CFB to C3b which forms
the AP C3 convertase, C3bBb, that cleaves C3 into C3b.
The resulting C3b can form another C3 convertase with
CFB and thereby creates a positive feedback amplification
mechanism that leads to rapid multiplication of C3b mole-
cules and complement effector proteins. The initial C3b is
generated by classical or lectin pathway activation or by
activated factors of the coagulation, contact activation and
fibrinolysis systems (reviewed in [14]). Subsequent
deposition of C3b on surfaces happens rapidly and is
indiscriminatory, targeting healthy self, altered self or for-
eign cells alike; however, binding of CFH or properdin
(required for stabilisation of the short lived AP C3 con-
vertase) enables the AP to distinguish between target sur-
faces [15, 16]. On a healthy self-surface, CFH binding
predominates and acts as a cofactor to CFI-mediated clea-
vage of C3b, whereas on foreign or altered self surfaces,
properdin binding enables assembly of C3 convertases that
amplify initial complement activation. If C3b is not
deposited on a surface but in the fluid phase, down-
regulation by CFH binding and CFI cleavage is heavily
favoured, with the generation of fluid-phase iC3b as an
inactive end product [17]. CFI is a key enzyme of the AP: in
the presence of a cofactor (CFH, Membrane Cofactor Pro-
tein, or Complement Receptor 1), it cleaves C3b into iC3b
and further into C3dg. Both cleavage reactions are essential
to prevent positive amplification of the alternative pathway
(by degradation of C3b into iC3b) and to degrade pro-
inflammatory iC3b into inert C3dg (Fig. 1A). Raising the
concentration of CFI in serum was found to inhibit initiation
of the AP [18]. The AP performs a continuous surveillance
function and is under strict control of plasma and membrane
bound complement regulator proteins. Due to the rapid self-
amplification mechanism, amplification via the AP may
account for more than 80% of all complement activation
[19]. Certain SNPs in several complement components can
predispose an individual to a more aggressive amplification
loop, deficient regulation on target surfaces or a less pro-
minent down regulation mechanism which is thought to
affect the risk of developing AMD as well as disease
severity. Supplementation of human serum with CFI was
shown to dampen an over-activated complement system in
high risk AMD sera by sequestering excess C3b via CFH
binding (which outcompetes Factor B) and degradation of
C3b required for AP C3 convertase formation [20]. It has
Fig. 1 Schematic diagram of the role of CFI in alternative pathway
regulation and AAV design. A CFI is a key regulator of the alter-
native pathway and degrades C3b into iC3b and C3dg in the presence
of cofactor. Figure adapted with permission from [12]. B Schematic
diagram of AAV2 backbone coding sequence. AAV= adeno-asso-
ciated virus, bGHpA= bovine growth hormone poly adenylation
sequence, bp= base pair, C3= Complement C3, CAG= chicken b-
actin promoter with a CMV enhancer and a β-globin intron, CFB=
complement factor B, CFD= complement factor D, CFH= comple-
ment factor H, CFI= complement factor I, CR1=Complement
Receptor 1, WPRE=Woodchuck hepatitis virus post-transcriptional
regulator element. Biorender.com was used to generate Fig. 1A, and B.
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therefore been considered that an increase in intra-ocular
CFI level has the potential to dampen an over-activated
complement system associated with AMD, reducing the
progression of the disease. Using ocular delivery of CFI by
gene therapy utilising Adeno-Associated Virus (AAV)
vectors, sustained expression of human CFI in AMD
patients and thereby reduction of local inflammation, might
be achieved. This therapy is proposed to reduce ongoing
inflammation at the site of the disease to slow down, pause
or maybe even revert disease progression.
Here, the generation of AAV viral vector constructs
carrying the cDNA of human CFI is described and suc-
cessful in vitro and in vivo expression of active protein in
human cell lines and murine retina is shown. These
encouraging pre-clinical studies have led to a first-in-human
AAV gene therapy trial for late-stage AMD
(NCT03846193).
Material and methods
Codon optimisation and generation of plasmids
The cDNA of the most common human CFI sequence
variant was downloaded from Genbank (Accession Number
NM_000204.4) and ordered as gBlocks® Gene Fragments
from Integrated DNA Technologies; this sequence is
referred to as CFI. Four different codon optimised versions
of the human CFI sequence were generated using publicly
available codon optimising tools (GenScript, Gene Art,
Integrated DNA Technologies and JCat); these codon-
optimised (co) sequences are subsequently referred to as
CFI.co-1, CFI.co-2, CFI.co-3 and CFI.co-4. All 5 constructs
were further modified by insertion of a Kozak consensus
sequence at the 5′-end. To generate pAAV.CFI, CFI cDNA
sequences were cloned into a synthesised AAV genome
backbone, consisting of 5′ and 3’ AAV2 inverted terminal
repeats (ITR), a modified CAG promoter (comprised of a
chicken β-actin promoter, a cytomegalovirus enhancer and a
rabbit β-globulin intron, collectively termed CAG promoter)
and a bovine growth hormone polyadenylation site. Addi-
tionally, a modified Woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) was added
downstream of the CFI cDNA sequence. WPRE was
included to enhance short-term and long-term AAV-medi-
ated transgene expression [21–23] and has been used in
multiple clinical trials without any safety concerns [24, 25].
Construction and production of AAV vectors
AAV vector was prepared by co-transfection of the HEK-
293 (ATCC) cell line with pAAV.CFI or pAAV.CFI.co
(pAAV.CFI.co-1 to pAAV.CFI-co.4) and pDG (Plasmid
Factory), the latter providing adenoviral helper sequences
and packaging sequences (Rep/Cap of AAV serotype 2).
This serotype was chosen to enable strong transduction
levels of the RPE and a lower level of transduction in the
neurosensory retina. HEK-293 cells were grown in DMEM
(Sigma) supplemented with 10% heat-inactivated foetal
bovine serum (Gibco), 1% 200 mM L-Glutamine (Sigma
Aldrich) and 1% Penicillin-Streptomycin (Sigma Aldrich).
Cells were harvested after 72 h and lysed to purify the viral
vector particles. These were purified using iodixanol gra-
dient centrifugation. Vector was concentrated on Amicon
Ultra-15 centrifugal filter units (Merck Millipore) and stored
at −70 °C. Vector purity was assessed by SDS PAGE and
the titre was determined by quantitative PCR.
Transfections and viral transductions
All constructs were tested in vitro prior to in vivo expression
studies in mice to confirm AAV, CFI transduction, expres-
sion and function. Cells were seeded in DMEM supple-
mented with 10% FBS at 1E+ 06 (HEK-293) or 6E+ 05
(ARPE-19) cells per well in a 6-well plate. Undifferentiated
ARPE-19 cells were used for all experiments and an AAV
carrying a GFP expression cassette was used as a negative
control. For transfections, cells were incubated with 2.5 µg
plasmid DNA and Lipofectamine LTX (Thermo Fisher Sci-
entific) according to manufacturer’s recommendations. For
transductions, cells were transduced at a MOI of 2.5E+ 03
with each AAV construct for 16 h, after which cells were
washed with PBS and incubated with fresh medium. Cells
were incubated for a total of 72 h following plasmid or AAV
delivery. Cells and supernatant were collected separately and
stored at −70 °C. Cell pellets were divided for simultaneous
analysis of protein and RNA expression.
Subretinal injection
Female 8–10 week old C57BL/6 J mice (Charles River
Laboratories) were used for all experiments. All animals were
treated humanely in accordance with the UK Home Office
Regulations under project license 30/3363. Mice were main-
tained on a 12:12-hour light/dark cycle. Mice were anaes-
thetised with a mixture of xylazine (10 mg/kg)/ketamine
(80mg/kg) in sterile saline; pupils were dilated with pheny-
lephrine hydrochloride (2.5%) and tropicamide (1%). Prox-
ymetacaine hydrochloride (0.5%) eye drops were used for
additional local anaesthesia. An anterior chamber tap was
performed prior to the subretinal injection using sterile 33 G
needles (TSK Laboratory) and carbomer gel (Viscotears,
Novartis Pharmaceuticals Ltd); and a small circular glass
coverslip was used to achieve good visualisation of the fun-
dus. The injection was performed through the posterior retina
using a 10 μL NanoFil syringe and a 35G bevelled NanoFil
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needle (World Precision Instruments Ltd). Anaesthesia was
reversed with atipamezole (2mg/kg) in sterile saline. Mice
were injected with AAV.CFI or AAV.CFI.co-1 viral vector at
two different doses (1E+ 07 genome copies (gc)/eye [low
dose] and 1E+ 08 gc/eye [high dose]) in a 2 µL total volume.
Prior to injection, vectors were diluted in 0.001% PF68
(Gibco) in PBS (Gibco). Sham injections were performed
using diluent only. Per viral vector and dose group, 6 mice
were injected in both eyes. After harvesting, eyes were dis-
sected as follows: first, a posterior eye cup dissection was
performed in 50 µL of PBS followed by retinal detachment
from the RPE/choroid/sclera complex (referred to as “RPE”
onwards). After retina and RPE tissue were isolated, both plus
the remaining eyeball tissue were flushed with the dissection
fluid enriched PBS. These isolated ‘wash’ sample and eye
tissues were immediately transferred to dry ice and stored at
−70 °C to prevent protein degradation. Tissues from three
mice were pooled for protein expression analysis as
described above.
Reverse transcriptase quantitative PCR (RT-qPCR)
RNA was extracted from cell pellets (in vitro) or homo-
genised eye tissues (in vivo) using an RNeasy mini kit
(Qiagen) as per manufacturer’s instructions. For quantifi-
cation of CFI RNA, iTaq Universal SYBR Green Supermix
(Bio-Rad) was used as per manufacturer’s instructions;
primer sequences are shown in Table S1. Samples were run
in a QuantStudio 6 Flex Real-time PCR system machine
(Thermo Fisher Scientific). Relative expression of CFI
(normalised to β-actin) was compared to the mean level in
the corresponding control groups; the fold difference in
expression was calculated using a qPCR efficiency cor-
rected delta-delta-Ct approach [26].
Immunoblotting
Cell pellets (in vitro) or homogenised eye tissues (in vivo)
were resuspended in radioimmunoprecipitation assay
(RIPA) buffer containing a proteinase inhibitor cocktail
(Sigma). Tissues of 3 eyes were pooled to ensure detection
of CFI protein. Protein concentrations of cell and tissue
lysates were determined using a BCA protein assay kit
(Thermo Scientific Pierce) as per the manufacturer’s
instructions. Western blotting was performed by separation
of proteins by means of SDS PAGE, followed by semi-dry
blotting and immunostaining of CFI, GFP or β-actin bands.
Equal volumes of cell culture supernatants were loaded and
for lysates, normalised amounts of protein, determined by
BCA protein assay, were loaded for each group. CFI was
detected with a mouse monoclonal antibody to human CFI
(1:500 dilution, OX21, Thermo Fisher Scientific) or a goat
anti-human CFI (1:1000 dilution, Comptech, A238). GFP
was detected with rabbit polyclonal antibody to TurboGFP
(1:1000 dilution, Thermo Fisher Scientific, PA5-22688) and
β-actin was detected with mouse anti-β-actin (1:10000
dilution, Thermo Fisher Scientific, AM4302). Protein bands
were visualised using Clarity Western ECL Substrate (Bio-
Rad) and analysed with an Odyssey® Fc Imaging System.
Immunoblots of transfected cells were analysed using
Image J software. In brief, bands were selected as region of
interest, plotted as histograms and the area under the curve
was calculated for each lane.
Preparation of retinal sections for
immunohistochemistry
Eyes were removed and a hole was made just behind the ora
serrata. The eyeball was placed in 4% (w/v) paraf-
ormaldehyde in 0.12M phosphate buffer, pH 7.2 for 1 hour
at room temperature. Next, the anterior segment and the lens
were removed, and the eyes were prepared for sections or
whole mount. Eye cups used for sections were cryopre-
served with increasing concentrations of sucrose rxin 0.12
M phosphate buffer, pH 7.2 (10%, for 1 h at room tem-
perature and 30% overnight at +4 °C), embedded in OCT
(Tissue-tek) and frozen in a mould at −70 °C. Sections were
cut at a thickness of 10 µm on a cryostat and mounted onto
glass slides (Super-Frost, Thermo Fisher Scientific). The
slides were air dried for 2 h at room temperature and stored
at −70 °C. For eye cups used for whole mounts, retina and
RPE/choroid were separated by gently peeling the retina off
the RPE and stored separately in PBS at +4 °C.
Immunostaining
Sections were blocked and permeabilised by incubation at
room temperature for 60 min in PBSGT solution (0.2%
(w/v) gelatine, 0.25% (v/v) Triton X-100 in PBS). Whole
mounts were blocked and permeabilized by incubation at
room temperature for 2 h in 0.2% (w/v) gelatine, 1.5% (v/v)
Triton X-100 in PBS. Subsequently, sections and whole
mounts were incubated with primary antibodies diluted in
PBSGT solution overnight at room temperature. CFI was
detected with rabbit anti-CFI (1:250 dilution, Sigma
Aldrich, HPA024061) and phalloidin (to visualise actin
filaments and cytoskeleton) was stained with Alexa Fluor
488 phalloidin (1:5,000, Life Technologies, A12379). After
washing in PBST solution (0.1% (v/v) Triton X-100 in
PBS), sections and whole mounts were incubated with goat
anti-rabbit secondary antibody coupled to Alexa Fluor594
(1:5000, Life Technologies, Thermo Fisher Scientific,
A32731) and stained with DAPI in PBSGT solution for
1.5 h at room temperature. The slides were washed with
PBST solution and subsequently cover-slipped with
mounting medium (Mowiol, Merck Millipore).
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C3b cleavage assay
A C3b cleavage assay was performed to confirm functional
activity of CFI expressed after subretinal injection in mice.
In this assay, the C3 alpha chain is degraded by CFI into
iC3b which can be detected by immunoblotting as a
reduction of the alpha chain at 116 kDa and appearance of
the two iC3b breakdown bands at 68 and 43 kDa. 20 µL of
dissection ‘Wash’ sample collected during dissection of
eyes was incubated with 1 µg purified C3b (Complement
Technology Inc.) and 0.5 µg purified CFH (Complement
Technology Inc.) for 1 hour at 37 °C. The same volume of
‘wash’ sample was standardised amongst all in vivo study
conditions to enable accurate comparison of FI functional
activity. C3b cleavage products were detected by western
blotting using a goat anti-human C3 antibody (1:5000
dilution, AbD Serotec/BioRad, AHP1752) and Peroxidase
conjugate AffiniPure Donkey Anti-goat IgG (1:5000,
Jackson ImmunoResearch, 705-035-147).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
8.4.0. If data were normally distributed with equal variance
then parametric tests were used (ANOVA) with Tukey’s or
Sidak’s multiple comparisons tests (Dunnett’s for data sets
with unequal variance). If data were not normally
distributed, then non-parametric tests were performed (Krus-
kal-Wallis) with Dunn’s multiple comparison test. Analyses
performed for each data set are stated in the respective figure
legends.
Results
Generation of 5 AAV.CFI viral vector constructs
Five AAV viral vectors were generated carrying either the
cDNA sequence of the human CFI gene or codon optimised
versions of the CFI sequence. A schematic diagram of the
vectors is shown in Fig. 1B. Codon optimised sequences of
CFI cDNA were generated using 4 different online tools as
described in methods. The 1752 bp CFI sequence was
placed under the control of the ubiquitous CAG promoter,
followed by a WPRE and a bovine growth hormone poly-A
site with AAV2 ITRs at each end (Fig. 1B).
CFI is expressed from human cell lines after
transfection and transduction
Generated pAAV.CFI and pAAV.CFI.co-1 to pAAV.CFI.
co-4 plasmid constructs were transfected into the ARPE-19
Fig. 2 Immunoblot analysis of supernatants and cell lysates of
pAAV.CFI, pAAV.CFI.co and pCMV.GFP co-transfected ARPE-
19 cells. A Upper immunoblot: Supernatants of transiently transfected
cells. CFI and codon-optimised CFI were detected with mouse anti-
human CFI. Plasmid backbone containing AAV sequences without
transgene served as a negative control (representative result). Supernatant
was loaded non-reduced to prevent separation of heavy and light chain.
Lower immunoblot: Lysate of transiently transfected cells. GFP was
detected with anti-turbo-GFP and implies that there were not large dif-
ferences in transfection efficiency between the groups. B Quantification
of CFI expression immunoblots by densitometry analysis using ImageJ
software. Equal volumes were loaded in each experiment and summary
data from 7 independent experiments is shown. Results are presented as
relative density of CFI signal relative to signal intensity of AAV.CFI.wt.
Data are shown as mean+ standard deviation. AAV= adeno-associated
virus, CFI= complement factor I, co= codon optimised. Asterisks
represent significant differences between codon optimised constructs and
the most common CFI sequence (reference) analysed by one-way
ANOVA and Dunn’s multiple comparison test: *=P < 0.05, **= P <
0.01, ns = not significant.
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Fig. 3 In vivo expression of CFI RNA and protein. A–D RT-qPCR
to analyse gene expression of AAV.CFI and AAV.CFI.co-1 (n= 3 per
condition) of whole eye cup (A), RPE (B), retina (C), and a com-
parison of all tissues analysed (D). RPE samples generated more CFI
mRNA than retina (p < 0.0001) and multiple comparisons revealed
significant differences between injection materials, which are descri-
bed in the text. Data are shown as mean+ standard deviation.
E Immunoblot of whole eye cups, retina, and RPE of mice injected
with AAV.CFI.wt or AAV.CFI.co-1, samples of three mice per con-
dition were pooled for analysis. β-actin staining was performed as a
loading control. AAV= adeno-associated virus, CFI= complement
factor I, co = codon optimised, ec= eye cup, ret = retina, RPE=
retinal pigment epithelium. Asterisks represent significant differences
between constructs analysed by one-way ANOVA with Tukey’s
multiple comparison: * = P < 0.05, ** = P < 0.01, *** = P < 0.001,
**** = P < 0.0001.
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cell line to confirm expression of CFI. Cells were co-
transfected with a Turbo-GFP plasmid to ensure that cells
were equally transfected. CFI was expressed from each
construct and protein was detected as a band at 63 kDa
(Fig. 2A, upper). Turbo-GFP staining, as a transfection
control, was similar in all transfected cells (Fig. 2A, lower).
Total CFI expression varied across constructs tested and
only one codon-optimised construct, pAAV.CFI.co-1,
yielded CFI concentrations similar to the wild-type CFI
sequence, pAAV.CFI. The other three constructs resulted in
significantly less CFI protein (Fig. 2B).
pAAV.CFI and pAAV.CFI.co-1 were selected and
packaged into AAV2 capsids. HEK-293 and ARPE-19
cells were transduced with AAV.CFI and AAV.CFI.co-1
at an MOI of 1E+ 04. CFI protein expression and
secretion were confirmed by immunoblotting and again
did not show differences in secreted levels of CFI
(Figure S2).
CFI is secreted from RPE cells and functionally active
after subretinal injection of AAV.CFI constructs
Female 8 to 10-week-old C57BL/6 J mice received a sub-
retinal injection via the transscleral route with two doses
(1E+ 07 [low dose] or 1E+ 08 vg/eye [high dose]) of
AAV.CFI or AAV.CFI.co-1 and CFI expression was ana-
lysed after 4 weeks. The expression of CFI in lysates of
mouse retinal tissues was confirmed by RT-qPCR analysis.
The tissue type, dose and injection material had a significant
influence on the relative mRNA levels of CFI. A strong
dose effect was observed in AAV.CFI in all tissues analysed
(Fig. 3A-D); however, a significant difference between high
and low dose of AAV.CFI.co-1 was only detected in the
retina (Fig. 3C). The RPE provided significantly more
relative CFI mRNA than other retinal tissue (Fig. 3D). No
CFI expression was detected in the control injected samples
(data not shown).
Fig. 4 Immunohistological analysis of retinal sections of AAV.CFI
and AAV.CFI.co-1 injected mouse eyes. 10 µm retinal sections of
sham (A–C), AAV.CFI (D–F) or AAV.CFI.co-1 (G–I) injected
mice stained with anti-phalloidin, DAPI, and anti-CFI to demon-
strate that CFI protein localises to the RPE cell layer and photo-
receptors. AAV= adeno-associated virus, CFI= complement factor
I, co = codon optimised, GCL= ganglion cell layer, IS= inner
segment of photoreceptors, NFL= nerve fibre layer; ONL= outer
nuclear layer, OPL= outer plexiform layer, OS= outer segment of
photoreceptors, RPE= retinal pigment epithelium, Scl= Sclera.
Magnification: ×20.
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Western blotting of lysed tissue fractions revealed CFI
protein with bands detected at 50 kDa (heavy chain) and 30
kDa (light chain) (Fig. 3E). Both AAV constructs resulted
in expression of CFI protein at each dose. Expression of
CFI was detected in all sample types and a trend for higher
expression in the eye cup sample was observed when band
intensity was compared visually. No human CFI was
detected in the control injected eyes.
Immunohistological analysis of eye cups was performed
to confirm RPE expression and to determine in vivo loca-
tion of CFI. Phalloidin and DAPI co-staining were used to
distinguish the different retinal layers. CFI protein was
detected in eyes of mice injected with AAV.CFI and AAV.
CFI.co-1 and localised mainly in two compartments: strong
expression was detected in the RPE and weaker expression
in both the outer and inner segments of photoreceptors
(Fig. 4 to Fig. 6 and Figure S3 to Figure S5). Wholemount
en face view of the posterior eye cup showed expression of
CFI protein in the hexagonal RPE cells (Fig. 6). The
staining appeared granular, which could indicate localisa-
tion of CFI within secretory pathway vesicles. Staining
intensity and location detected in AAV.CFI and AAV.CFI.
co-1 injected mouse eye retinal sections was similar,
although CFI immunoreactivity appeared to be more
punctate in AAV.CFI (Fig. 4F) and more linear (Fig. 4I) in
AAV.CFI.co-1 injected eyes staining at the junction of OPL
and INL retinal layers.
Due to the small volume in mice, it is not easy to directly
analyse the vitreous humour for presence and processing of
secreted CFI protein. During dissection of eyes, tissues were
rinsed with PBS and used as “wash” sample for functional
testing of CFI protein by a C3b cleavage assay. Presence
and activity of CFI is measured by degradation of C3b and
detected by immunoblotting. Figure 7 shows that control
injected “wash” samples have low C3b processing activity,
as evidenced by only partial degradation of the C3 alpha
chain into 68 and 43 kDa iC3b bands, likely due to low
levels of endogenous mouse CFI expression. AAV.CFI
injected “wash” samples showed increased C3b degradation
and complete degradation of the C3 alpha band into the
iC3b breakdown bands, demonstrating that CFI was both
secreted and functional (Fig. 7, only AAV.CFI was ana-
lysed in this assay).
Discussion
This paper describes the development and characterisation
of five vectors for a gene therapy to treat AMD. These
results show for the first time, in vivo expression of active
human CFI protein in mice. By subretinal injection, it is
possible to target the majority of AAV.CFI constructs to the
RPE which sits between Bruch’s membrane and photo-
receptors. CFI is a complement regulator that only through
Fig. 5 Immunohistological analysis retinal sections of sham and
AAV.CFI injected mouse eyes – higher magnification of RPE.
Immunohistological analysis retinal sections of sham (A-C) and AAV.
CFI (D-F) injected mouse eyes. Retinal sections were double labelled
with phalloidin to stain actin filaments (A, D) and CFI (B, E). Nuclei
were stained with DAPI and are shown in merge (C, F). Vesicular
staining is depicted with arrows, RPE microvilli are highlighted with
asterisk. AAV= adeno-associated virus, BrM: Bruch’s membrane,
CFI= complement factor I, Chr: choriocapillaris, IPM: inter photo-
receptor matrix, RPE: retinal pigment epithelium, Scl: sclera.
Magnification: 189x.
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post-translational modification is converted from a single
polypeptide chain (pro-CFI) into the dimeric active enzyme.
Furin cleaves pro-CFI into a heavy and a light chain [27]
and only then is CFI able to bind to the C3b-FH complex
and orientate its light chain containing the serine protease
domain to enable cleavage of C3b into iC3b [28]. In vitro
expression of CFI often results in incomplete processing
probably due to insufficient furin processing activity [27]
and therefore reduced activity of recombinant CFI protein.
Here, over-expression of CFI protein in mouse retinas
resulted in fully active CFI that is able to cleave its natural
substrate C3b into iC3b when tested ex vivo.
Of note, western blot and RT-qPCR analysis do not
correlate with respect to which tissue has the highest CFI
expression; however, a dose-effect is observed in both
analyses with AAV.CFI resulting in higher CFI expression
levels than AAV.CFI.co-1. The reason for the discrepancy
between both methods could be low sample numbers and
the fact that three tissue samples were pooled for immu-
noblot analysis.
Codon optimisation as employed in this study is often
used to increase levels of recombinant proteins. Most amino
acids are encoded by multiple synonymous codons but the
relative expression of individual tRNAs can vary dramati-
cally across species and even cell or tissue types [29].
Codon optimisation tools aim at maximising expression
rates by either adjusting codon usage to resemble the natural
distribution of the host organism by removing rare codons
in exchange for more frequently used codons or by avoiding
occurrences of codon-pairs that are known to translate
slowly (reviewed in [30]). Rapid translation is, however, not
always beneficial and it is thought that translation some-
times is slowed down by rare codon usage to enable correct
folding of certain protein domains [31]. Therefore, codon
Fig. 6 Immunohistological analysis of whole mounted RPE of
AAV.CFI and AAV.CFI.co-1 injected mouse eyes. Whole mounted
RPE of sham (A-C), AAV.CFI (D-F) and AAV.CFI.co-1 (G-I)
injected mice was stained with anti-phalloidin and anti-CFI. CFI is
highly expressed in RPE cells of AAV.CFI.wt and AAV.CFI.gs
treated mice. Abbreviations: AAV= adeno-associated virus, CFI=
complement factor I, co = codon optimised. Magnification: 40x.
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optimisation does not always lead to higher protein
expression, as shown in this study, and highlights our
limited understanding of codon usage in transgene expres-
sion. It is also noteworthy that, although correct protein
sequence will be retained, SNPs introduced due to alter-
native codon usage can result in unanticipated alteration of
RNA sequences by removal of pre-existing and/or intro-
duction of novel editing sites [30], thereby creating novel or
even pathogenic gene sequences. All downstream effects of
a codon optimised sequence should therefore be critically
evaluated before permanent and sustained expression by
gene therapy to avoid potentially serious consequences. In
this study, none of the four tested codon optimised
sequences were found to enhance expression in vitro and
in vivo.
Current drug development efforts and clinical studies for
the treatment of AMD and/or geographic atrophy focus on
inhibition of the complement system, anti-inflammatory
drugs, neuroprotection, reduction of toxic by-products,
improvement of mitochondrial function, and stem cell
therapies [31]. After a first wave of drug candidates tar-
geting the complement system failed to meet clinical end-
points in AMD and/or geographic atrophy (for example
Lampalizumab [Genentech Inc., Roche, NCT02247479
and NCT02247531], Eculizumab [Alexion Pharmaceu-
ticals Inc., NCT00935883], LFG316 [Novartis Pharma-
ceuticals], LFG316 [Novartis Pharmaceuticals,
NCT02515942]), a plethora of new therapeutic approaches
are currently in clinical development [32]. The exact rea-
sons for the failure of previously tested complement ther-
apeutics are unknown. However, it is likely to be a
combination of the chosen target proteins, mode of deliv-
ery, nature of drug, insufficient levels for protection or
unfavourable diffusion properties within the eye and
through Bruch’s membrane. Alternatively, it is also possi-
ble that intervention by targeting the complement system is
less efficient in geographic atrophy and would need to be
applied during earlier stages of the disease. Overall, they
also underline the fact that there is currently still a limited
understanding of how complement activation is regulated
in AMD. Over the last year; however, positive results of
phase 2 interventional trials have been announced which
support the complement system as a drug target in the
treatment of geographic atrophy: APL, a C3 inhibitor
developed by Apellis Pharmaceuticals, Inc (NCT03525600
and NCT03525613) and Zimura, a C5 inhibitor, developed
by Iveric bio, formerly Ophthotech Corporation
(NCT02686658). Overexpression of CFI in the eye has the
potential of restoring local complement activation accom-
panying AMD and thereby slowing down progression of
atrophy. In contrast to other complement inhibitors which
aim to completely abolish complement activation,
increasing levels of CFI will re-balance the complement
system to prevent excessive activation whilst maintaining
low levels of complement turnover required to maintain
homoeostasis in the eye [33]. As shown by Lachmann et al.
[20], an increase in plasma concentration of CFI by 50% is
sufficient to protect serum from donors with an AMD at-
risk genetic composition from complement hyperactiva-
tion. In the absence of an approved therapeutic treatment of
late stage AMD, local CFI supplementation might have the
potential to slow down disease progress by limiting com-
plement mediated inflammation in the eye. The data pre-
sented here led to the formulation of the GT005 product
which is now under evaluation in a first-in-human clinical
trial delivering an AAV gene therapy for late stage AMD
(Gyroscope Therapeutics Ltd, NCT03846193).
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Fig. 7 Ex vivo demonstration of CFI functional activity by a
cofactor assay following subretinal administration. C3b, the sub-
strate, is incubated with CFH as a cofactor; in the absence of CFI no
degradation occurs (lane ‘C3b + CFH’, assay negative control). As
soon as C3b is incubated with CFH and CFI, degradation of C3b into
iC3b occurs, visible as 68 and 43 kDa bands (lane ‘C3b + CFH+CFI,
assay positive control). C3 and CFH are incubated with ‘wash’ sample
derived from either sham injected or AAV.CFI injected mice as a
source of CFI and degradation of the C3 alpha band into the iC3b
bands is observed. Abbreviations: AAV= adeno-associated virus,
C3= complement C3, CFI= complement factor I, CFH= comple-
ment factor H.
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